DS
ENTA icon

David Shaw’s Enanta Pharmaceuticals ENTA Stock Holding History

David Shaw’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,000
Closed -$580K – 3780
2018
Q2 		$580K Hold
5,000
– – ﹤0.01% 3031
2018
Q1 		$405K Buy
+5,000
New +$385K ﹤0.01% 2982

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

David Shaw's ENTA Position: Q2 2026 in Review

David Shaw reduced its Enanta Pharmaceuticals (ENTA) stake by 51% in Q2 2026, selling an estimated $489K and leaving 34,539 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #4176.

David Shaw first reported a position in ENTA in Q3 2014 and has held it in 38 quarters since. The position peaked at $9.96M in Q1 2024. 121 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • David Shaw held 34,539 shares of Enanta Pharmaceuticals worth $504K as of Q2 2026.
  • David Shaw sold 36,345 Enanta Pharmaceuticals shares in Q2 2026, an estimated $489K.
  • Enanta Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4176 holding.
  • David Shaw first reported a position in Enanta Pharmaceuticals in Q3 2014 and has held it in 38 quarters since.
  • David Shaw's Enanta Pharmaceuticals position peaked at $9.96M in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.